LifeSciences BC > News > Member Announcements

InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview

January 21, 2020
InMed Pharmaceuticals Inc.

Vancouver, BC – January 21, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today published additional information describing in detail its leading cannabinol-based therapeutics programs on its … Continue reading InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview

InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials

January 20, 2020
InMed Pharmaceuticals Inc.

Vancouver, BC – January 20, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing therapeutics targeting diseases with high unmet medical needs, today revealed the rare cannabinoid  cannabinol (“CBN”) as the active pharmaceutical ingredient (“API”) in its two product candidates under development: INM-755 for epidermolysis bullosa (“EB”) … Continue reading InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials

Chinook Therapeutics Obtains Worldwide Rights from AbbVie to Atrasentan with Plans to Develop for the Treatment of Kidney Diseases

January 17, 2020
Chinook Therapeutics Inc.

VANCOUVER, British Columbia–(BUSINESS WIRE)–Chinook Therapeutics, Inc., a biotechnology company focused on developing precision medicines for kidney diseases, today announced it has entered into a license agreement with AbbVie, a research-based global biopharmaceutical company, for worldwide, exclusive rights to atrasentan, an endothelin receptor antagonist. Chinook will assume all development and commercialization responsibilities for atrasentan globally. Chinook … Continue reading Chinook Therapeutics Obtains Worldwide Rights from AbbVie to Atrasentan with Plans to Develop for the Treatment of Kidney Diseases

InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress

January 16, 2020

VANCOUVER, January 16, 2020 /CNW/ — InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced that members of its senior scientific and clinical team will be attending the EB2020 World Congress, sponsored by the Dystrophic Epidermolysis Bullosa Research … Continue reading InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress

Shimadzu Medical Systems USA and NZ Technologies sign agreement to bring TIPSO AirPad Technology to the IXR Suite

January 14, 2020
NZ Technologies Inc.

TORRANCE, Calif., Jan. 13, 2020 /PRNewswire/ — Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation and a leader in diagnostic medical imaging systems, along with NZ Technologies of Vancouver Canada and developers of TIPSOTM technology, today announced that they have signed a one-year renewable agreement that allows Shimadzu to market and sell the innovative TIPSO AirPad® in the US healthcare market. … Continue reading Shimadzu Medical Systems USA and NZ Technologies sign agreement to bring TIPSO AirPad Technology to the IXR Suite

InMed Pharmaceuticals to Present at the Biotech Showcase Conference

January 13, 2020
InMed Pharmaceuticals Inc.

VANCOUVER, January 8, 2020 /CNW/ — InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced that Eric A. Adams, President & CEO will be presenting at the Biotech Showcase conference to be held at the Hilton San Francisco … Continue reading InMed Pharmaceuticals to Present at the Biotech Showcase Conference

InMed Announces Election of Directors

January 13, 2020
InMed Pharmaceuticals Inc.

Vancouver, BC – January 10, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today confirmed that at its annual general meeting of shareholders held on December 19, 2019 (the “Meeting”), all directors nominated as listed in the … Continue reading InMed Announces Election of Directors

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update

January 13, 2020
Xenon Pharmaceuticals Inc.

Xenon’s Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020 Xenon Eligible for Milestone Payments Based on the Advancement of Partnered Programs Experienced Biotech Executive, Dr. Clarissa Desjardins, Joins Xenon’s Board of Directors BURNABY, British Columbia, Jan. 13, 2020 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), … Continue reading Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update

Onestep Laboratories developed QuickRedTM (the first) small molecular Near Infrared nucleus stain for living cell imaging

January 9, 2020
Onestep Laboratories Inc.

The nucleus is a highly specialized organelle that serves as the information processing and administrative center of the cell. This organelle has two major functions: it stores the cell’s hereditary material, or DNA, and it coordinates the cell’s activities, which include growth, intermediary metabolism, protein synthesis, and reproduction (cell division). The nucleus is the information … Continue reading Onestep Laboratories developed QuickRedTM (the first) small molecular Near Infrared nucleus stain for living cell imaging

adMare BioInnovations and Accel-Rx Unite to Advance the Canadian Life Sciences Sector

January 9, 2020
adMare BioInnovations

Vancouver, Canada – January 9, 2020: With a shared vision to be a catalyst for Canadian life sciences leading the world, adMare BioInnovations, Canada’s Global Life Sciences Venture (adMare), and Accel-Rx, Canada’s Health Sciences Accelerator (Accel-Rx), announced today they are bringing their respective capabilities and resources together under adMare to create a world leading organization. … Continue reading adMare BioInnovations and Accel-Rx Unite to Advance the Canadian Life Sciences Sector